CLSD logo

CLSDClearside Biomedical Inc

$0.31
$0.0302
(8.88%)
Today
Updated: 10:52 AM EDT
Reported EarningsAug 18
Mkt Cap$1.78M
Vol5,269.00
News
all
press releases
CLSD Stock Plummets After Company Files For Bankruptcy Protection
The biopharmaceutical company is seeking authorization to pursue an auction and sale process.
Stocktwits
News Placeholder
More News
News Placeholder
Clearside Biomedical, Inc. (CLSD) Reports Q3 Loss, Lags Revenue Estimates
Clearside Biomedical (CLSD) delivered earnings and revenue surprises of -70.15% and -23.57%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks
News Placeholder
Mersana Therapeutics, Inc. (MRSN) Reports Q3 Loss, Lags Revenue Estimates
Mersana Therapeutics (MRSN) delivered earnings and revenue surprises of -4.86% and -18.85%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks
News Placeholder
Orchestra BioMed Holdings, Inc. (OBIO) Reports Q3 Loss, Beats Revenue Estimates
Orchestra BioMed Holdings, Inc. (OBIO) delivered earnings and revenue surprises of -5.26% and +15.42%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks
News Placeholder
AbCellera Biologics Inc. (ABCL) Reports Q3 Loss, Tops Revenue Estimates
ABCELLERA BIOLG (ABCL) delivered earnings and revenue surprises of -11.76% and +35.31%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks
News Placeholder
Clearside Biomedical, Inc. (CLSD) Reports Q2 Loss, Beats Revenue Estimates
Clearside Biomedical (CLSD) delivered earnings and revenue surprises of +50.00% and +87.07%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks
News Placeholder
Compugen (CGEN) Reports Q2 Loss, Lags Revenue Estimates
Compugen (CGEN) delivered earnings and revenue surprises of -14.29% and -76.15%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks
News Placeholder
Clearside Biomedical (CLSD) Upgraded to Buy: Here's What You Should Know
Zacks
News Placeholder
Clearside Biomedical, Inc. (CLSD) Reports Q1 Loss, Tops Revenue Estimates
Zacks
News Placeholder
Lineage Cell (LCTX) Reports Q1 Loss, Lags Revenue Estimates
Zacks
<
1
2
...
>

Advertisement|Remove ads.